Table 1 Baseline data of 206 hepatocellular carcinoma patients

Age (years)

 Median (IQR)

54.00 (48.00, 60.00)

56 (50.00, 61.75)

55 (52.00, 62.00)

-1.581

0.134

 Range

19.00–72.00

31.00–81.00

26.00–72.00

Gender

 Male

118

59

52

0.082

0.960

 Female

20

9

8

AFP (ng/mL)

 < 20

57

24

23

0.710

0.701

 ≥ 20

81

44

37

Hepatitis B virus

 Yes

113

62

53

3.646

0.162

 No

25

6

7

Hepatitis C virus

 Yes

5

3

3

0.469

0.850

 No

133

64

57

Liver cirrhosis

 Yes

97

50

45

0.545

0.762

 No

41

18

15

Buga

 Yes

5

4

3

0.830

0.734

 No

133

64

57

Preoperative ALT (U/L)

 ≥ 40

50

20

26

2.681

0.262

 < 40

88

48

34

Preoperative AST (U/L)

 ≥ 40

51

19

26

3.367

0.186

 < 40

87

49

34

Tumor size

 ≤ 2 cm

23

14

9

0.775

0.679

 > 2 cm

115

54

51

Child–Pugh score

 A

127

61

56

0.587

0.746

 B–C

11

7

4

Hepatic encephalopathy

 Yes

0

0

0

 No

138

68

60

Ascitic fluid

 Yes

11

3

6

1.516

0.469

 No

127

65

54

Bilirubin (μmol/L)

 < 25

121

59

51

0.264

0.877

 ≥ 25

17

9

9

Albumin (μmol/L)

 35–55

103

57

49

2.724

0.256

 < 35 or > 55

35

11

11

Prothrombin time prolonged

 4–6

0

0

0

 > 6

138

68

60

Complete capsule

 Complete

73

33

26

2.036

0.729

 Incomplete

52

29

29

 No

13

6

5

Peritumoral enhanced

 Yes

24

10

14

1.687

0.430

 No

114

58

46

Smooth edge

 Yes

72

38

31

0.307

0.858

 No

66

30

29

Intratumoral arteries

 Negative

88

49

35

2.728

0.256

 Positive

50

19

25

Peritumoral low density

 Negative

101

54

46

1.007

0.605

 Positive

37

14

14

TTPVI

 Negative

103

52

42

0.744

0.689

 Positive

35

16

18

Tumor-liver difference

 Clear

107

45

40

4.100

0.129

 Unclear

31

23

20

RVI

 Negative

125

61

52

0.685

0.710

 Positive

13

7

8